|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
MIB-1 indices were elevated in 18/21 (86%) carcinomas.
|
27490759 |
2018 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The frequency of MIB-1 (Ki-67) expression-positive OC increased with increasing FIGO stage (p = 0.003), increasing histological grade (p ≤ 0.0001), and a significantly different distribution of MIB-1 (Ki-67) positive and negative tumours were found in adenocarcinoma NOS, serous adenocarcinomas, mucinous adenocarcinomas, endometrioid adenocarcinomas, non-epithelial and clear-cell carcinomas (p = 0.016).
|
23594232 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The MIB-1 fraction in most signatures was less than 5%, and ranged from 50 to 90% in carcinomas.
|
19151662 |
2009 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Strong PARP expression was determined in 38 cases (76%), and low expression in 12 cases (12%) of ovarian serous carcinomas; MIB-1 staining was noted in all cases (mean, 44.2; range, 10.8-66.5), positivity for p53 in 39 cases (78%).
|
17413981 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
MIB1-positive cell index of the carcinomas had a direct correlation with the expression levels of ADAM28m and ADAM28s (r = 0.667, p < 0.001 and r = 0.535, p < 0.01, respectively).
|
16052521 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The average percentage of MIB-1-positive cells increased steadily from cystadenomas (7.5%) to borderline tumors (22.6%) to carcinomas (41.2%).
|
10684699 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fifty-three neuroendocrine lung tumors (24 carcinoids, one atypical carcinoid, five large-cell neuroendocrine carcinomas, and 23 small-cell lung carcinomas) were investigated for immunocytochemical expression of several gene products, i.e., p53, Rb, bcl-2, c-kit, mdm-2, cdk-4, p21 proteins, and proliferation index as assessed by MIB-1.
|
10937049 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the study was twofold: 1) to investigate any correlation between MIB1 and bcl-2 immunostaining expression in colonic adenomas and carcinomas, 2) to identify any relationship between either marker and several histopathologic parameters including tumor size, pathologic stage, lymph node metastasis, angio-lymphatic invasion, tumor grade and differentiation in colon carcinomas.
|
10607921 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Seeking a potential correlation, we investigated tumor cell apoptosis, proliferation, and angiogenesis in the adenoma-carcinoma sequence of colorectal carcinogenesis using an in situ apoptosis detection kit and MIB-1 and anti-CD34 antibodies in 27 adenomas with low dysplasia, 17 adenomas with high dysplasia, and 26 carcinomas in adenoma, as well as assessed p53 and bcl-2 expressions.
|
9918211 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the DNA content did not correlate significantly with the age, sex, or survival of the patients, nor the length, location, differentiation and MIB-1 labelling index of the oesophageal carcinomas.
|
9038733 |
1996 |